Form 4 for ORKA Oruka Therapeutics, Inc.
Accepted 2026-06-15 18:52:55 ET · period of report 2026-06-15 · accession 0000907654-26-000062 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-15 18:52 | 2026-06-15 | ORKA | Klein Lawrence Otto | CEO, Dir | S - Sale | $69.69 | -1,729 | 925.6K | -0.2% | -$120.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-15 | S | D | 1,729 | $69.69 | 925,580 | D | — | — | (F1) The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. |